A descriptive study on multisystem inflammatory syndrome in children in a single center in West Michigan

Jonathan Shabab1, Allysen Dubisky2, Ambaris Singh1

  • 1Spectrum Health Helen DeVos Children's Hospital/Michigan State University Pediatric Residency Program, Grand Rapids, MI, USA.

Abstract

Insights

Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare condition post-SARS-CoV-2. Anakinra and steroids show promise for treatment, with ferritin and BNP as potential severity biomarkers.

Area of Science:

  • Pediatric critical care medicine
  • Infectious diseases
  • Rheumatology

Background:

  • Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare, hyperinflammatory condition following SARS-CoV-2 infection.
  • Limited research exists on MIS-C risk factors, management, and outcomes.
  • This study addresses the need for further understanding of MIS-C.

Purpose of the Study:

  • To describe the clinical, imaging, and laboratory characteristics of MIS-C patients.
  • To detail treatments and outcomes, comparing intensive care unit (PICU) and non-PICU patients.
  • To identify potential biomarkers for MIS-C severity.

Main Methods:

  • Case series of 26 MIS-C patients diagnosed between April 2020 and February 2021.
  • Analysis of clinical, imaging, and laboratory data.
  • Statistical comparisons between PICU and non-PICU groups using Chi-square, Fisher's Exact, T-tests, and Kruskal-Wallis tests.

Main Results:

  • Gastrointestinal symptoms (84%) and Kawasaki-like features (65%) were common; 46% developed coronary artery dilation.
  • Fifteen patients (57%) required PICU admission; all Black patients required intensive care.
  • Higher peak ferritin, procalcitonin, and BNP levels were associated with PICU admission.

Conclusions:

  • MIS-C is a distinct, heterogeneous disorder with significant cardiac involvement.
  • Anakinra combined with steroids appears safe and effective for MIS-C treatment.
  • Procalcitonin, peak ferritin, and BNP may serve as useful biomarkers for disease severity.